Novavax publishes positive efficacy data for its COVID-19 vaccine
Novavax today published positive data from the UK phase three study of its COVID-19 vaccine candidate, showing it to be 89.3% effective in preventing coronavirus in participants.
The study was conducted during the period the new COVID-19 variant was first observed in Kent and began to circulate widely, with today’s results showing it was effective against the variant during the phase three trial.
Thanks to the work of the government’s Vaccines Taskforce, the UK has secured 60 million doses of Novavax’s vaccine to be delivered in the second half of this year, if approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA), who will assess whether the vaccine meets robust standards of safety, effectiveness and quality.
Last August Novavax announced plans to manufacture the bulk of the vaccine using FUJIFILM Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees. This will ensure that, once available, the vaccine can be supplied to the British public as soon as possible.
Business Secretary Kwasi Kwarteng said: “The results from the UK trial of Novavax’s vaccine look extremely promising, and I welcome the news that the company is planning to submit its data to the regulators. The UK moved quickly to procure 60 million doses from Novavax and I’m pleased to confirm the bulk of the vaccine will be manufactured on Teesside and delivered during this year, if approved for use.
“From the scientists and researchers to the thousands of UK trial volunteers, I am enormously grateful to everyone who is playing their part in this truly national effort to defeat this virus once and for all.”